Why Akebia Therapeutics, Inc.’s (AKBA) Stock Is Up 6.15%
As of Tuesday, July 07, Akebia Therapeutics, Inc.’s AKBA share price has surged by 6.15%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090, which is in Phase 2 clinical trial for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries; Vafseo License and Collaboration Agreements; CSL Vifor Agreements; Averoa License Agreement; License Agreement with Panion & BF Biotech, Inc.; Cyclerion Therapeutics License Agreement; and Q32 Asset Purchase Agreement. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Commentary & Analysis
Why Akebia Therapeutics, Inc.’s (AKBA) Stock Is Up 5.24%
As of Monday, July 06, Akebia Therapeutics, Inc.’s AKBA share price has surged by 5.24%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Akebia Therapeutics, Inc.’s (AKBA) Stock Is Up 5.25%
As of Wednesday, July 01, Akebia Therapeutics, Inc.’s AKBA share price has surged by 5.25%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Akebia Therapeutics, Inc.’s (AKBA) Stock Is Up 5.89%
As of Tuesday, June 16, Akebia Therapeutics, Inc.’s AKBA share price has surged by 5.89%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Akebia Therapeutics, Inc.’s (AKBA) Stock Is Down 5.05%
As of Wednesday, June 10, Akebia Therapeutics, Inc.’s AKBA share price has dipped by 5.05%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | AKBA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $362.1 | $251.9 | 34% |
|
| Shares Out (Mil) | 267.0 | 50.8 | 81% |
|
| Institutional Ownership | 94.6% | 92.0% | 65% |
|
| Float (Mil) | 262.0 | 40.5 | 78% |
|
| Beta | 0.35 | 0.95 | 20% |
|
| Avg Daily Volume (000s) | 2,112 | 447 | 83% |
|
| Price Change (52-week) |
(61.3%) | 54.2% | 12% |
|
| Growth | AKBA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (4.3%) | 14.0% | 9% |
|
| Net Income (5yr) | 57.6% | (9.8%) | 95% |
|
| EPS (5yr) | 62.4% | 16.3% | 96 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (2.5%) | (15.6%) | 63% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 2 | |
| Current EPS | ($0.025) | ($0.105) | ($0.190) | |
| Month Ago EPS | ($0.025) | ($0.105) | ($0.190) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.005) | ($0.020) | ($0.160) | |
| Year/Year Chg | (26.5%) | 400.0% | 447.6% | |
| Financials | AKBA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $232 | $39 | 34% |
|
| Net Income (TTM) (Mil) | ($21) | ($43) | 24% |
|
| EPS (TTM) | ($0.077) | ($1.600) | 37% |
|
| Operating Cash Flow (TTM) (Mil) | $60 | ($30) | 48% |
|
| Net Cash Flow (TTM) (Mil) | $49 | $3 | 71% |
|
| Long-Term Debt (Q1) (Mil) | $158 | $5 | 48% |
|
| Enterprise Value (Q1) (Mil) | $338 | $182 | 31% |
|
| Valuation | AKBA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 13.60 | 2.60 | 93% |
|
| P/E | na | 18.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | AKBA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 81.9% | 63.8% | 90% |
|
| Net Margin | (8.8%) | (64.7%) | 22% |
|
| ROA | (6.1%) | (49.7%) | 29% |
|
| ROE | (79.0%) | (55.4%) | 11% |
|
| Liabilities to Assets | 92.4% | 30.3% | 90% |
|
| F-Score | 5 | 3 | 51% |
|
Akebia Therapeutics, Inc. did not pass any screens on 7/30/2026.
